

Isofol's board appoints Thomas Andersson as new CEO of the company

Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the board of Isofol has decided to appoint Thomas Andersson as CEO of the company from February 28, 2023. As a consequence of this decision, the current CEO, Ulf Jungnelius, is resigning and is now being dismissed from his position.

Thomas Andersson (b. 1952) has long experience from leading positions in the pharmaceutical industry, including as CEO of Spectracure, Senior Advisor at Karolinska Institutet Innovations AB, Investment Manager at Karolinska Development AB, CEO of Lund University Bioscience AB, Head of Cell Therapy at Bavarian Nordic AS and CEO of Annexin Pharmaceuticals AB. He has been part of the founding of more than 15 companies, held over 20 board assignments and is currently Senior Advisor Business Development at Oslo Cancer Cluster Incubator as well as board member of Kongsberg Beam Technology AS, Thepler AS and Skogsmöllan AB. Thomas Andersson has a PhD in physical chemistry from Lund University.

"We are very happy to be able to welcome Thomas Andersson as Isofol's new CEO. With his extensive experience in company management, drug development and business development, he has excellent background to create value for patients and shareholders based on the company's drug candidate arfolitixorin," says Mats Franzén, chairman of the board of Isofol Medical AB (publ).

Thomas Andersson succeeds Ulf Jungnelius, who has been CEO of the company since 2019.

For more information, please contact

Isofol Medical AB (publ)

Mats Franzén, Chairman of the Board

E-mail: mats@efficere.se

Phone: +46 (0) 704 47 29 09

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.45 CET on February 28, 2023.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical-stage biotechnology company that has focused its operations on developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol's ambition was to develop a drug for first-line treatment of advanced colorectal cancer (mCRC), thereby seeking to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with



Merck & Cie in Schaffhausen, Switzerland, to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com